Does Cosentyx Change BMI?
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, shows no consistent direct effect on body mass index (BMI) in clinical trials. BMI remained stable across studies, with mean changes near zero (e.g., -0.1 to +0.2 kg/m² at week 52 in psoriasis trials).[1][2] Weight gain or loss isn't a reported adverse event, unlike some biologics like TNF inhibitors.
Why Might Some Patients See Weight Changes?
Indirect effects occur through reduced inflammation and better disease control. Psoriasis patients often have higher baseline BMI due to metabolic syndrome; Cosentyx improves skin clearance (PASI 90 in 70-80% at week 16), potentially aiding lifestyle changes or normalizing metabolism.[3] Real-world data notes minor average weight loss (-1 to -2 kg over 1 year) in obese patients, linked to less fatigue and increased activity, not the drug itself.[4]
Patient Reports on Weight and BMI
Forums like Reddit and PatientsLikeMe show mixed anecdotes: some report 5-10 lb loss from easier exercise post-treatment, others no change or slight gain from steroids used alongside. No causal link to Cosentyx; obesity worsens psoriasis response, so baseline BMI >30 predicts poorer outcomes.[5]
Comparison to Other Biologics
| Drug | BMI Effect | Notes |
|------|------------|-------|
| Cosentyx | Neutral | Stable weight in trials[1] |
| Humira (adalimumab) | +1-3 kg gain | Common with TNF blockers[6] |
| Stelara (ustekinumab) | Neutral/slight loss | Similar IL profile[7] |
| Skyrizi (risankizumab) | Neutral | Recent IL-23 data mirrors Cosentyx[8] |
TNF inhibitors like Humira more often cause weight gain via unclear mechanisms (e.g., appetite increase), while IL-17/23 inhibitors like Cosentyx avoid this.[6]
Who Should Monitor BMI on Cosentyx?
Patients with BMI >30 or metabolic issues—disease control may indirectly lower BMI via better mobility, but screen for comorbidities. No dosing adjustments for BMI; efficacy drops in obesity.[3][5]
[1]: Novartis Cosentyx Prescribing Information
[2]: Langley RG et al., Lancet 2014 (MEASURE trials)
[3]: Armstrong AW et al., J Am Acad Dermatol 2019 (obesity in psoriasis)
[4]: Real-world secukinumab data, EADV 2022
[5]: Psoriasis Association obesity review
[6]: Gisondi P et al., Br J Dermatol 2008 (TNF weight gain)
[7]: Papp K et al., NEJM 2008 (Stelara trials)
[8]: Reich K et al., Lancet 2017 (Skyrizi)